Not a good buy right now for an impatient investor: trend structure is bearish (SMA_200 > SMA_20 > SMA_5) and fundamentals weakened sharply in the latest quarter.
With price (~11.34 pre-market) below the pivot (11.987) and no proprietary buy signals today, odds favor waiting rather than chasing.
Near-term setup is mixed: MACD is improving, but it’s not yet enough to override the broader downtrend and weak profit/margin trend.
No notable hedge fund/insider momentum, no recent news catalysts, and no congress trading signals to provide extra conviction.
Technical Analysis
Trend: Bearish overall (SMA_200 > SMA_20 > SMA_5), suggesting the broader direction remains downward.
Momentum: MACD histogram is positive (0.0321) and expanding, indicating a potential early bounce/turn attempt.
RSI (6): ~50.0 (neutral), showing no strong overbought/oversold edge.
Key levels: Pivot 11.987 (price below = resistance overhead). Support S1 10.948 then S2 10.306; Resistance R1 13.026 then R2 13.668.
Pattern-based forward odds (similar candlesticks): ~40% chance of -0.43% next day; +4.6% next week; +2.53% next month (moderate upside bias beyond the very near term, but not high confidence).
No analyst rating or price target change data was provided, so recent Wall Street rating/target trend cannot be verified from this dataset.
Wall Street-style pros (based on provided data): modest revenue growth and potential technical bounce (improving MACD).
Wall Street-style cons (based on provided data): severe YoY deterioration in earnings and margins plus a bearish longer-term technical structure.
Politicians/congress/influential trading: No recent congress trading data available in the last 90 days.
Wall Street analysts forecast CHCI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CHCI is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast CHCI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CHCI is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
